[go: up one dir, main page]

FR20C1057I2 - BROADCAST DELIVERY OF GENES TO MOTOR NEURONS BY PERIPHERAL INJECTION OF AAV VECTORS - Google Patents

BROADCAST DELIVERY OF GENES TO MOTOR NEURONS BY PERIPHERAL INJECTION OF AAV VECTORS

Info

Publication number
FR20C1057I2
FR20C1057I2 FR20C1057C FR20C1057C FR20C1057I2 FR 20C1057 I2 FR20C1057 I2 FR 20C1057I2 FR 20C1057 C FR20C1057 C FR 20C1057C FR 20C1057 C FR20C1057 C FR 20C1057C FR 20C1057 I2 FR20C1057 I2 FR 20C1057I2
Authority
FR
France
Prior art keywords
genes
motor neurons
aav vectors
broadcast delivery
peripheral injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1057C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Genethon
Original Assignee
Centre National de la Recherche Scientifique CNRS
Genethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1057(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS, Genethon filed Critical Centre National de la Recherche Scientifique CNRS
Publication of FR20C1057I1 publication Critical patent/FR20C1057I1/en
Application granted granted Critical
Publication of FR20C1057I2 publication Critical patent/FR20C1057I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
FR20C1057C 2007-10-05 2020-11-17 BROADCAST DELIVERY OF GENES TO MOTOR NEURONS BY PERIPHERAL INJECTION OF AAV VECTORS Active FR20C1057I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301435A EP2058401A1 (en) 2007-10-05 2007-10-05 Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP08836776.8A EP2212424B2 (en) 2007-10-05 2008-10-03 Widespread gene delivery to motor neurons using peripheral injection of aav vectors
PCT/EP2008/063297 WO2009043936A1 (en) 2007-10-05 2008-10-03 Widespread gene delivery to motor neurons using peripheral injection of aav vectors

Publications (2)

Publication Number Publication Date
FR20C1057I1 FR20C1057I1 (en) 2020-12-25
FR20C1057I2 true FR20C1057I2 (en) 2024-02-16

Family

ID=39186802

Family Applications (2)

Application Number Title Priority Date Filing Date
FR20C1057C Active FR20C1057I2 (en) 2007-10-05 2020-11-17 BROADCAST DELIVERY OF GENES TO MOTOR NEURONS BY PERIPHERAL INJECTION OF AAV VECTORS
FR22C1056C Active FR22C1056I1 (en) 2007-10-05 2022-11-17 WIDESPREAD GENE DELIVERY TO MOTOR NEURONS USING PERIPHERAL AAV VECTOR INJECTION

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR22C1056C Active FR22C1056I1 (en) 2007-10-05 2022-11-17 WIDESPREAD GENE DELIVERY TO MOTOR NEURONS USING PERIPHERAL AAV VECTOR INJECTION

Country Status (19)

Country Link
US (3) US9926574B2 (en)
EP (5) EP2058401A1 (en)
JP (2) JP5620819B2 (en)
CN (2) CN101883859A (en)
CA (2) CA2999607A1 (en)
CY (2) CY1125608T1 (en)
DK (2) DK3505635T3 (en)
ES (3) ES2727034T3 (en)
FI (1) FI2212424T4 (en)
FR (2) FR20C1057I2 (en)
HR (2) HRP20140643T1 (en)
HU (2) HUE059864T2 (en)
LT (2) LT3505635T (en)
LU (1) LUC00285I2 (en)
NO (1) NO2022048I1 (en)
PL (2) PL3505635T3 (en)
PT (3) PT2212424E (en)
SI (2) SI2212424T1 (en)
WO (1) WO2009043936A1 (en)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
EP2019143A1 (en) * 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (en) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
SG10202109219SA (en) 2009-05-02 2021-10-28 Genzyme Corp Gene therapy for neurodegenerative disorders
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
ES2698203T3 (en) * 2010-04-23 2019-02-01 Univ Massachusetts AAV vectors that are directed to the SNC and methods of using them
CA3050894C (en) 2010-04-23 2022-10-18 University Of Massachusetts Multicistronic expression constructs
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
US10738326B2 (en) 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
US9226976B2 (en) 2011-04-21 2016-01-05 University Of Massachusetts RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US20130039888A1 (en) * 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
EP4124346A3 (en) * 2012-06-19 2023-04-19 University of Florida Research Foundation, Inc. Compositions and methods for treating diseases
EP2864488A1 (en) * 2012-06-21 2015-04-29 Association Institut de Myologie Widespread gene delivery of gene therapy vectors
BR112015002168A2 (en) 2012-08-01 2017-11-07 Nationwide Childrens Hospital intrathecal release of recombinant adeno-associated virus 9
JP2015529685A (en) 2012-09-17 2015-10-08 ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Compositions and methods for the treatment of amyotrophic lateral sclerosis
SG11201509419QA (en) 2013-05-15 2015-12-30 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
PL3702466T3 (en) 2013-08-27 2023-04-24 Research Institute At Nationwide Children's Hospital Products and methods for treatment of amyotrophic lateral sclerosis
AU2014346987A1 (en) 2013-11-05 2016-06-23 The Research Institute At Nationwide Children's Hospital Compositions and methods for inhibiting NF-kB and SOD-1 to treat amyotrophic lateral sclerosis
ES2821938T3 (en) * 2014-03-09 2021-04-28 Univ Pennsylvania Compositions useful in the treatment of ornithine transcarbamylase deficiency (OTC)
EP2933335A1 (en) * 2014-04-18 2015-10-21 Genethon A method of treating peripheral neuropathies and motor neuron diseases
US10689653B2 (en) 2014-06-03 2020-06-23 University Of Massachusetts Compositions and methods for modulating dysferlin expression
BR112017001725A2 (en) 2014-07-31 2018-02-14 Association Inst De Myologie amyotrophic lateral sclerosis treatment
EP3795580A1 (en) 2014-10-03 2021-03-24 University of Massachusetts High efficiency library-identified aav vectors
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
AU2015335923B2 (en) 2014-10-21 2021-04-29 University Of Massachusetts Recombinant AAV variants and uses thereof
CN114717264A (en) 2014-11-14 2022-07-08 沃雅戈治疗公司 Compositions and methods for treating amyotrophic lateral sclerosis (ALS)
CN114480440A (en) 2014-11-21 2022-05-13 北卡罗来纳-查佩尔山大学 AAV vectors targeting the central nervous system
CA2967468A1 (en) 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
US20180104289A1 (en) 2015-04-08 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Viral gene therapy as treatment for cholesterol storage disease or disorder
CA3021949C (en) 2015-04-24 2023-10-17 University Of Massachusetts Modified aav constructs and uses thereof
AU2016332847B2 (en) * 2015-10-01 2023-08-10 Goleini Inc. Targeted expression of chloride channels and methods of use thereof
AU2016341983B8 (en) * 2015-10-21 2022-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Codon-optimized reduced-size ATP7A cDNA and uses for treatment of copper transport disorders
CA3002980A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
ES2978086T3 (en) 2015-10-22 2024-09-05 Univ Massachusetts Aspartoacylase gene therapy in the treatment of Canavan disease
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING AN ADENO-ASSOCIATED VIRUS (AAV)
US12036268B2 (en) * 2015-11-19 2024-07-16 Universitat Autònoma De Barcelona Secreted splicing variant of mammal Klotho as a medicament for cognition and behaviour impairments
CA3011939A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
WO2017176929A1 (en) 2016-04-05 2017-10-12 University Of Massachusetts Compositions and methods for selective inhibition of grainyhead-like protein expression
BR112018071156A2 (en) 2016-04-15 2019-03-12 The Trustees Of The University Of Pennsylvania gene therapy to treat mucopolysaccharidosis type ii
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance
CN109415730A (en) 2016-06-13 2019-03-01 北卡罗来纳大学教堂山分校 Optimized CLN1 gene and expression cassettes and their applications
US11882815B2 (en) 2016-06-15 2024-01-30 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
KR20190075964A (en) 2016-10-13 2019-07-01 유니버시티 오브 매사추세츠 AAV capsid design
CN108524952A (en) * 2017-03-06 2018-09-14 复旦大学 Adeno-associated virus AAV9 and its purposes in the preparation for preparing treatment dagger-axe Xie Shi diseases
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND TREATMENT METHODS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS)
AU2018302016A1 (en) 2017-07-17 2020-02-06 The Regents Of The University Of California Trajectory array guide system
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
KR102883778B1 (en) 2017-09-22 2025-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Gene therapy for the treatment of type II mucopolysaccharidosis
CA3077426A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111566220A (en) 2017-11-08 2020-08-21 阿维克斯公司 Means and methods for preparing viral vectors and uses thereof
BR112020015798A2 (en) 2018-02-01 2021-03-09 Homology Medicines, Inc. COMPOSITIONS OF ADEN-ASSOCIATED VIRUSES TO RESTORE PAH GENE FUNCTION AND METHODS OF USING THE SAME
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
US11306329B2 (en) 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
AU2019247746B2 (en) 2018-04-03 2024-08-15 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
KR20210006358A (en) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 Viral vectors for targeting the inner tissues
US12054724B2 (en) 2018-04-10 2024-08-06 President And Fellows Of Harvard College AAV vectors encoding clarin-1 or GJB2 and uses thereof
US20210230632A1 (en) 2018-05-15 2021-07-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
US20210214749A1 (en) 2018-05-16 2021-07-15 Voyager Therapeutics, Inc. Directed evolution
JP7478675B2 (en) 2018-06-08 2024-05-07 ノバルティス アーゲー Cell-Based Assays for Measuring the Potency of Drug Products
US12163129B2 (en) 2018-06-08 2024-12-10 University Of Massachusetts Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
WO2020010035A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Cannula system
EP3818161A1 (en) 2018-07-02 2021-05-12 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
MX2021000810A (en) 2018-07-24 2021-04-28 Voyager Therapeutics Inc Systems and methods for producing gene therapy formulations.
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
TW202035689A (en) 2018-10-04 2020-10-01 美商航海家醫療公司 Methods for measuring the titer and potency of viral vector particles
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2020117898A1 (en) 2018-12-05 2020-06-11 Abeona Therapeutics Inc. Recombinant adeno-associated viral vector for gene delivery
TW202039858A (en) 2019-01-18 2020-11-01 美商航海家醫療公司 Methods and systems for producing aav particles
MX2021009161A (en) * 2019-02-05 2021-09-10 Univ Princeton RECOMBINANT NUCLEIC ACIDS CONTAINING ALPHAHERPESVIRUS PROMOTER SEQUENCES.
CN109706176A (en) * 2019-03-12 2019-05-03 青岛大学附属医院 Construction method of adenovirus vector for targeted transfection of dorsal root ganglion satellite glial cells
MX2021011468A (en) 2019-03-21 2021-12-15 Recombinant adeno-associated virus vectors.
MX2021011701A (en) * 2019-03-28 2021-12-10 Massachusetts Gen Hospital Engineered adeno-associated (aav) vectors for transgene expression.
CN114450031A (en) * 2019-07-10 2022-05-06 洛卡纳生物股份有限公司 Targeted RNA knockdown and replacement compositions and methods of use
US20220288235A1 (en) * 2019-08-20 2022-09-15 St. Jude Children's Research Hospital, Inc. SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
WO2021041489A1 (en) * 2019-08-29 2021-03-04 The Board Of Trustees Of The Leland Stanford Junior University Adeno-associated viral vectors for crossing the human blood brain barrier
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
WO2021076925A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
TW202140791A (en) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 Methods of treating phenylketonuria
EP4135841A1 (en) 2020-04-15 2023-02-22 Voyager Therapeutics, Inc. Tau binding compounds
CA3182970A1 (en) 2020-05-13 2021-11-18 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
TW202208632A (en) 2020-05-27 2022-03-01 美商同源醫藥公司 Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
IL300717A (en) 2020-08-19 2023-04-01 Sarepta Therapeutics Inc Adeno-associated virus vectors for treatment of rett syndrome
US12129287B2 (en) 2020-09-14 2024-10-29 President And Fellows Of Harvard College Recombinant adeno associated virus encoding clarin-1 and uses thereof
CN112121179A (en) * 2020-09-15 2020-12-25 山东兴瑞生物科技有限公司 Composition and application thereof in treating spinal muscular atrophy
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN115708866A (en) * 2021-08-23 2023-02-24 中国科学院深圳先进技术研究院 Application of bone origin factor RANKL in preparation of medicine or medicine composition for regulating and controlling central nervous system homeostasis
US20250223376A1 (en) 2021-09-20 2025-07-10 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
JP2024540221A (en) 2021-11-02 2024-10-31 ボイジャー セラピューティクス インコーポレイテッド AAV capsid variants and uses thereof
WO2023091948A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
KR20240161976A (en) 2022-02-08 2024-11-13 보이저 테라퓨틱스, 인크. AAV capsid variants and uses thereof
IL316719A (en) 2022-06-02 2024-12-01 Voyager Therapeutics Inc Aav capsid variants and uses thereof
EP4547690A1 (en) 2022-06-28 2025-05-07 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
TW202424201A (en) 2022-07-06 2024-06-16 美商航海家醫療公司 Aav capsid variants and uses thereof
EP4565597A2 (en) 2022-08-03 2025-06-11 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
CN116064671A (en) * 2022-08-10 2023-05-05 深圳先进技术研究院 Application of a gene delivery system to deliver genes to microglia
CA3266790A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
IL320511A (en) 2022-12-29 2025-06-01 Voyager Therapeutics Inc Compositions and methods for regulating mapt
WO2024226790A1 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
TW202444917A (en) 2023-05-04 2024-11-16 美商航海家醫療公司 Aav capsid variants and uses thereof
WO2025038430A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2025147436A1 (en) 2024-01-03 2025-07-10 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2222574A1 (en) 1995-06-07 1996-12-19 Yale University Oral delivery of adeno-associated viral vectors
US20040076613A1 (en) 2000-11-03 2004-04-22 Nicholas Mazarakis Vector system
FR2756297B1 (en) 1996-11-22 1999-01-08 Centre Nat Rech Scient PROCESS FOR PRODUCING RECOMBINANT VIRUSES
JP2001512142A (en) 1997-07-31 2001-08-21 カイロン コーポレイション Method for enabling re-administration of AAV vectors via immunosuppression of the host
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
AU1071701A (en) 1999-09-29 2001-04-30 Trustees Of The University Of Pennsylvania, The Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
AU1775901A (en) 1999-11-17 2001-05-30 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
ES2256265T3 (en) * 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill DUVICATED PARVOVIRUS VECTORS.
AU2001268149B2 (en) 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
CA2452980A1 (en) 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
SG10201506627PA (en) * 2001-11-13 2015-10-29 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
ES2526341T3 (en) 2001-12-17 2015-01-09 The Trustees Of The University Of Pennsylvania Sequences of serotype 9 of adeno-associated virus (AAV), vectors containing them, and uses thereof
JP2005516949A (en) 2001-12-19 2005-06-09 リジュン・ワン Adeno-associated virus-mediated delivery of GDNF to skeletal muscle
US6998118B2 (en) * 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
NZ533833A (en) * 2001-12-21 2008-01-31 Salk Inst For Biological Studi Targeted retrograde gene delivery to motor neurons
WO2006002283A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
US20050095225A1 (en) * 2003-03-31 2005-05-05 Engelhardt John F. Compounds and methods for pharmico-gene therapy of epithelial sodium channel associated disorders
WO2004106517A1 (en) * 2003-06-03 2004-12-09 Benitec Australia Limited Double-stranded nucleic acid
PT2657248T (en) 2003-06-19 2017-06-26 Genzyme Corp Aav virions with decreased immunoreactivity and uses therefor
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
CN102212558B (en) * 2003-09-30 2016-08-03 宾夕法尼亚大学托管会 Adeno associated virus (AAV) is evolved, sequence, carrier containing these sequences and their application
CA2542417A1 (en) * 2003-10-14 2005-04-28 Neurologix Research, Inc. Methods and compositions for the treatment of neurological disease
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
WO2005056807A2 (en) 2003-12-04 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Bovine adeno-associated viral (baav) vector and uses thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
JP2007531537A (en) * 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein AI and apolipoprotein A-IMLANO
US20060110364A1 (en) * 2004-08-20 2006-05-25 Ludwig Institute For Cancer Research Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
JP5766389B2 (en) 2005-05-02 2015-08-19 ジェンザイム・コーポレーション Gene therapy for spinal cord disease
WO2007089632A2 (en) * 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
US20070280906A1 (en) 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
EP2132309A4 (en) * 2007-02-23 2011-01-05 Univ Florida COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES RELATED TO GLYCOGEN STORAGE
US10696983B2 (en) 2007-05-30 2020-06-30 The Trustees Of The University Of Pennsylvania Method for transducing cells with primary cilia
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
US20090087413A1 (en) 2007-10-01 2009-04-02 Alcon Research, Ltd. Self-complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
US11219696B2 (en) * 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9

Also Published As

Publication number Publication date
ES2482094T5 (en) 2024-06-03
EP3505635B1 (en) 2022-05-18
EP2212424B1 (en) 2014-06-11
DK2212424T3 (en) 2014-07-14
LTPA2022525I1 (en) 2022-12-12
FR20C1057I1 (en) 2020-12-25
WO2009043936A1 (en) 2009-04-09
LUC00285I2 (en) 2025-05-12
HUE059864T2 (en) 2023-01-28
JP2010540598A (en) 2010-12-24
SI2212424T1 (en) 2014-12-31
CN105087650A (en) 2015-11-25
CY2022034I1 (en) 2023-06-09
US20200010852A1 (en) 2020-01-09
CA2701561C (en) 2018-05-15
US11767538B2 (en) 2023-09-26
EP2212424B2 (en) 2023-11-01
FR22C1056I1 (en) 2023-01-06
EP2058401A1 (en) 2009-05-13
ES2924892T3 (en) 2022-10-11
PT3505635T (en) 2022-08-12
HUS2200047I1 (en) 2022-12-28
HRP20140643T1 (en) 2014-11-07
JP6309373B2 (en) 2018-04-11
US20100240739A1 (en) 2010-09-23
HRP20220992T3 (en) 2022-11-11
US9926574B2 (en) 2018-03-27
LT3505635T (en) 2022-09-12
CY1125608T1 (en) 2023-06-09
PT2527457T (en) 2019-05-31
PT2212424E (en) 2014-07-25
ES2482094T3 (en) 2014-08-01
NO2022048I1 (en) 2022-11-16
EP2527457B1 (en) 2019-02-20
CA2999607A1 (en) 2009-04-09
FI2212424T4 (en) 2023-12-15
CA2701561A1 (en) 2009-04-09
CN101883859A (en) 2010-11-10
EP2527457A1 (en) 2012-11-28
JP2014221789A (en) 2014-11-27
EP3854878A1 (en) 2021-07-28
US20180066283A1 (en) 2018-03-08
DK3505635T3 (en) 2022-08-22
PL2212424T3 (en) 2014-11-28
ES2727034T3 (en) 2019-10-11
PL3505635T3 (en) 2022-09-12
SI3505635T1 (en) 2022-10-28
EP3505635A1 (en) 2019-07-03
JP5620819B2 (en) 2014-11-05
EP2212424A1 (en) 2010-08-04
CY2022034I2 (en) 2023-06-09

Similar Documents

Publication Publication Date Title
FR20C1057I2 (en) BROADCAST DELIVERY OF GENES TO MOTOR NEURONS BY PERIPHERAL INJECTION OF AAV VECTORS
FR20C1058I1 (en) GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEM BY PERIPHERAL DELIVERY OF AAV VECTOR
CL2007003879A1 (en) COMPOUNDS DERIVED FROM ARIL-CARBOXAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS ALZHEIMER, EPILEPSY AND PARKINSON.
EP2303337A4 (en) MEDICAMENT-LIGAND SMALL MOLECULE CONJUGATES FOR TARGETED CANCER TREATMENT
HRP20180739T1 (en) INJECTION FORMULATIONS OF BOTULIN TOXIN
EP2244357A4 (en) ENGINE
EP2588129A4 (en) DEGRADATION OF PROTEIN TARGETED BY SMALL MOLECULES
EP2194582A4 (en) ORGANIC THIN FILM TRANSISTOR
EP2334176A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF NEUROPATHY
BRPI0917497A2 (en) plasma renin mass spectrometry assay
CL2009000990A1 (en) Use of epothilone d for the treatment of diseases associated with tau, such as Alzheimer's disease, Parkinson's, among others.
IL210813A0 (en) Methods of administering topical antifungal formulations for the treatment of fungal infections
FI20070063A0 (en) Organic field effect transistor
EP2128422A4 (en) EVAPORATED FUEL TREATMENT APPARATUS
BRPI0909653A2 (en) stabilized transdermal therapeutic system
DE602008005797D1 (en) engine
EP2362909A4 (en) INFECTIONS INVOLVED MIRACLE GENES
FR2934817B1 (en) VEHICLE OF SMALL SIZE.
EP2287113A4 (en) FUEL TREATMENT APPARATUS
IT1391506B1 (en) MOTOR AXIS
PL2304212T3 (en) Solid-propellant rocket motor
BRPI0909364A2 (en) multi fuel engine fuel injection control device
SE0850158L (en) Fuel injection device for engine
EP2734644A4 (en) ENGINE GENES OF OLIGODENDROGLIOME
BRPI0716766A2 (en) Amino Alcohol Nitrate Esters